Buy Daclatasvir
Daclatasvir
Daclatasvir Properties
About Daclatasvir
Generic Daclatasvir is oral antiviral medication approved in Australia for the treatment of chronic hepatitis C virus (HCV) infection. It belongs to the class of NS5A inhibitors and is typically prescribed in combination with other direct-acting antivirals such as sofosbuvir. The standard tablet strength is 60 mg, taken once daily. By targeting a key protein in the viral replication complex, Daclatasvir helps to suppress viral load, reduce liver inflammation, and increase the chance of a sustained virologic response (SVR), which is considered a cure. While its primary indication is HCV, clinicians sometimes consider it in clinical trials for other viral infections under strict supervision.
What is Generic Daclatasvir?
Generic Daclatasvir is a ribonucleic acid (RNA) virus inhibitor that blocks the non-structural protein 5A (NS5A) of the hepatitis C virus. The Therapeutic Goods Administration (TGA) approved it in 2016, and it is listed on the Australian Register of Therapeutic Goods (ARTG) as a prescription-only medicine. As a generic product, it contains the same active ingredient as the branded version (Daklinza) and must meet the same bioequivalence standards, offering a cost-effective alternative for patients and health-care systems. It is supplied as a 60 mg film-coated tablet, intended for oral administration.
How Daclatasvir Works
Daclatasvir binds with high affinity to domain I of the HCV NS5A protein, a phosphoprotein that orchestrates the formation of the replication complex and the assembly of viral particles. By disrupting NS5A, the drug interferes with both RNA replication and virion assembly, leading to a rapid decline in viral RNA levels. Pharmacokinetic studies show that peak plasma concentrations occur within 2-4 hours after a single dose, and the drug’s half-life is approximately 12-15 hours, supporting once-daily dosing. It is metabolised primarily by cytochrome P450 3A4 (CYP3A4) and excreted in the feces; hepatic impairment can increase exposure, so dose adjustments may be required. Because Daclatasvir does not significantly affect the QT interval, it can be combined safely with many other antivirals, provided drug-drug interactions are managed.
Why Daclatasvir is Used for Infections Conditions
-
Chronic Hepatitis C Genotype 1, 2, 3, 4, 5, and 6 Mechanism link: NS5A inhibition halts replication of all major HCV genotypes, making Daclatasvir a pan-genotypic option. Guideline position: The Australian Therapeutic Guidelines recommend an NS5A inhibitor plus a polymerase inhibitor (e.g., sofosbuvir) as a first-line regimen for most chronic HCV patients. Comparison: Compared with earlier interferon-based therapies, Daclatasvir-based regimens achieve SVR rates >95 % with fewer side effects and a shorter treatment course (typically 12 weeks).
-
HCV Patients with Compensated Cirrhosis Mechanism link: Even in scarred liver tissue, suppressing NS5A reduces viral load enough to allow hepatic regeneration. Guideline position: For compensated cirrhosis, the Daclatasvir-sofosbuvir combination is endorsed, often extended to 24 weeks for genotype 3 to improve outcomes. Comparison: This regimen avoids the haemoglobin-lowering effects of ribavirin, which were common in older protocols for cirrhotic patients.
-
HCV/HIV Co-infection Mechanism link: The drug’s metabolic pathway (CYP3A4) overlaps with several antiretrovirals, necessitating careful selection of compatible agents. Guideline position: When compatible antiretrovirals are used, Daclatasvir-based therapy remains a first-line option, delivering cure rates comparable to HCV-mono-infection. Comparison: It eliminates the need for interferon, which interacts adversely with many HIV medications.
Is Daclatasvir Right for You?
Patients most likely to benefit are adults with confirmed chronic HCV infection who have no contraindications to NS5A inhibition. The medication is suitable for treatment-naïve individuals as well as those who have previously failed therapy, provided resistance-associated substitutions (RAS) are assessed. Special populations that require extra consideration include:
- Pregnant or breastfeeding women - safety data are limited; the medication is generally avoided.
- Elderly patients - pharmacokinetics are similar to younger adults, but comorbidities and polypharmacy raise the risk of drug-drug interactions.
- Renal impairment - no dose adjustment is needed for mild to moderate renal dysfunction; severe impairment should be evaluated by a specialist.
As noted in the medication information, the presence of certain cardiac conditions, uncontrolled infections, or hypersensitivity to Daclatasvir components would preclude use. Clinicians also review liver function, as decompensated cirrhosis may require alternative regimens.
Taking Daclatasvir Effectively
- Timing: Take the 60 mg tablet once daily, preferably at the same time each day to maintain steady plasma levels.
- Food: The tablet can be swallowed with or without food; however, a light snack may reduce occasional gastrointestinal upset.
- Concurrent meds: Because Daclatasvir is metabolised by CYP3A4, avoid strong inducers (e.g., rifampicin, St John’s wort) and discuss any over-the-counter supplements with your pharmacist.
- Missed dose: If you miss a dose, take it as soon as you remember unless the next scheduled dose is within 12 hours; in that case, skip the missed tablet and continue the regular schedule. Do not double-dose.
- Travel: Carry a sufficient supply for the entire course plus extra tablets in case of delays. Keep the medication in its original container to protect it from heat and moisture.
- Adherence: Completing the full prescribed course, even if you feel better early, is essential for achieving SVR and preventing viral resistance.
Understanding Side Effects and How to Manage Them
Most patients tolerate Daclatasvir well, but some experience mild, predictable reactions that stem from its systemic exposure:
- Headache - likely due to central nervous system penetration; hydrate well and use acetaminophen if needed.
- Fatigue - often improves after the first week; schedule low-intensity activities and maintain regular sleep patterns.
- Nausea or abdominal discomfort - take the tablet with food, sip clear fluids, and avoid heavy, fatty meals.
- Diarrhoea - stay hydrated, consider oral rehydration solutions, and limit caffeine or dairy if they worsen symptoms.
Serious adverse events such as hepatic decompensation, severe rash, or cardiac arrhythmias are rare but require immediate medical attention. If you notice jaundice, dark urine, rapid weight gain, or palpitations, contact a health-care professional promptly.
Buying Daclatasvir from Our Online Pharmacy
Our pharmacy service is dedicated to making essential antivirals accessible across Australia, especially for patients in remote areas or those facing high out-of-pocket costs.
Why Choose Our Service?
- Convenient ordering - browse, select, and confirm your purchase from any device.
- Secure checkout - all transactions are encrypted and comply with Australian privacy laws.
Quality & Safety
We partner with licensed international wholesalers that adhere to WHO Good Manufacturing Practices and hold certifications from the TGA. Each batch of Daclatasvir undergoes independent verification to ensure potency and purity before it leaves the warehouse.
Pricing & Access
Because generic Daclatasvir is priced significantly lower than branded equivalents, our platform offers competitive discounts-typically 20 % to 30 % off retail pharmacy rates. Repeat orders qualify for a lifetime 10 % discount, helping you maintain therapy without financial strain.
Discreet Delivery
Orders are packaged in plain, tamper-evident containers. Express shipping delivers within approximately 7 days to most capitals, while standard delivery arrives within 3 weeks to regional locations. Tracking information is provided at every stage.
Frequently Asked Questions
-
What genotypes of hepatitis C can Daclatasvir treat? Daclatasvir is active against all major HCV genotypes (1-6), making it a versatile option in pan-genotypic regimens.
-
Do I need to take ribavirin with Daclatasvir? Modern guidelines reserve ribavirin for specific, hard-to-treat cases; most patients achieve cure without it, reducing the risk of anaemia.
-
Can Daclatasvir be used if I have mild liver fibrosis? Yes. The drug is approved for patients with any degree of fibrosis, from early-stage disease to compensated cirrhosis, provided liver function tests are within acceptable limits.
-
How does Daclatasvir interact with common heart medications? Since it is metabolised by CYP3A4, drugs such as certain calcium-channel blockers or statins may require dose adjustments. Your prescriber will review all concurrent medicines.
-
Is Daclatasvir safe for people with HIV? When paired with antiretrovirals that do not strongly induce or inhibit CYP3A4, Daclatasvir can be co-administered safely, achieving cure rates similar to HCV-only patients.
-
What should I do if I experience severe fatigue? Report persistent fatigue to your clinician; they may reassess timing, evaluate for anaemia, or adjust accompanying antivirals.
-
Can I store Daclatasvir in a bathroom cabinet? The tablet is stable at room temperature (15-30 °C) but should be kept away from moisture and direct sunlight; a bedroom drawer is preferable.
-
Why is a baseline viral load test required before starting therapy? Measuring HCV RNA helps determine the length of treatment and monitors early virologic response, which predicts the likelihood of achieving SVR.
-
Are there any dietary restrictions while on Daclatasvir? No specific restrictions exist, but excessive alcohol can worsen liver disease and should be avoided.
-
How soon after completing treatment will my liver enzymes normalise? Most patients see a gradual decline in ALT/AST within weeks, but complete normalisation may take several months, especially in those with advanced fibrosis.
Glossary
- NS5A
- A non-structural protein of hepatitis C virus essential for replication and assembly of viral particles; the primary target of Daclatasvir.
- Sustained Virologic Response (SVR)
- The absence of detectable HCV RNA in the blood 12 weeks after completing therapy, regarded as a virological cure.
- CYP3A4
- An enzyme in the liver that metabolises many drugs, including Daclatasvir; inhibitors or inducers of this enzyme can alter drug levels.
Disclaimer
The information provided about Daclatasvir is for general knowledge only and does not replace professional medical consultation. All treatment decisions, including those regarding off-label use, should be made under the supervision of a qualified healthcare provider. Readers are assumed to be responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to Daclatasvir for individuals who may have limited availability through traditional pharmacies, prescription-based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication.
